Get notified when RGNX files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsREGENXBIO reports Phase III RGX-202 Duchenne trial data and Q1 2026 earnings
Filed May 14, 2026 · Period ending May 14, 2026 · ~1 min read
Key Changes
-
high
Company presented topline and interim results from pivotal Phase III AFFINITY DUCHENNE trial evaluating RGX-202 gene therapy for Duchenne muscular dystrophy. Detailed data available in press release exhibit.
Item 8.01 verify on EDGAR → -
medium
REGENXBIO disclosed Q1 2026 financial results for quarter ended March 31, 2026. Specific financial figures, revenue, and guidance contained in attached press release.
Item 2.02 verify on EDGAR → -
medium
Two separate press releases attached as exhibits: one covering quarterly earnings (Exhibit 99.1) and one covering RGX-202 trial data (Exhibit 99.2). 8-K body contains no detailed metrics.
Item 9.01 verify on EDGAR →
This preview is just the start — the full report includes the narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.
Want to see a complete report first? Today's free report (TRV 10-Q) is open in full — no account needed.
Partner
Trade RGNX commission-free
Open an account, get a free stock.
Investing involves risk. Free stock terms apply.
Thanks — your feedback helps us improve report quality.
Source-verified from EDGAR · Narrative written by AI · Jun 4, 2026 · How we verify